We are analyzing https://link.springer.com/article/10.1007/s00259-005-1762-7.

Title:
Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease | European Journal of Nuclear Medicine and Molecular Imaging
Description:
The demographics of aging suggest a great need for the early diagnosis of dementia and the development of preventive strategies. Neuropathology and structural MRI studies have pointed to the medial temporal lobe (MTL) as the brain region earliest affected in Alzheimer’s disease (AD). MRI findings provide strong evidence that in mild cognitive impairments (MCI), AD-related volume losses can be reproducibly detected in the hippocampus, the entorhinal cortex (EC) and, to a lesser extent, the parahippocampal gyrus; they also indicate that lateral temporal lobe changes are becoming increasingly useful in predicting the transition to dementia. Fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) imaging has revealed glucose metabolic reductions in the parieto-temporal, frontal and posterior cingulate cortices to be the hallmark of AD. Overall, the pattern of cortical metabolic changes has been useful for the prediction of future AD as well as in distinguishing AD from other neurodegenerative diseases. FDG-PET on average achieves 90% sensitivity in identifying AD, although specificity in differentiating AD from other dementias is lower. Moreover, recent MRI-guided FDG-PET studies have shown that MTL hypometabolism is the most specific and sensitive measure for the identification of MCI, while the utility of cortical deficits is controversial. This review highlights cross-sectional, prediction and longitudinal FDG-PET studies and attempts to put into perspective the value of FDG-PET in diagnosing AD-like changes, particularly at an early stage, and in providing diagnostic specificity. The examination of MTL structures, which has so far been exclusive to MRI protocols, is then examined as a possible strategy to improve diagnostic specificity. All told, there is considerable promise that early and specific diagnosis is feasible through a combination of imaging modalities.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,626,432 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We see no obvious way the site makes money.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

google, scholar, disease, alzheimers, dementia, neurol, brain, glucose, neurology, article, pet, pubmed, cognitive, hippocampal, atrophy, aging, cerebral, imaging, metabolism, impairment, cas, mild, leon, psychiatry, alzheimer, early, diagnosis, mri, temporal, metabolic, med, tomography, ann, study, lobe, emission, positron, magnetic, resonance, normal, obrien, herholz, fdgpet, memory, neurobiol, convit, studies, entorhinal, cortex, patients,

Topics {✒️}

2-[18f]fluoro-2-deoxy-d-glucose/positron-emission tomography high-resolution technetium-99m-hmpao spect 18f-fluoro-2-deoxy-d-glucose hypothalamic-pituitary-adrenal axis function month download article/chapter magnetic resonance imaging nincds-adrda work group review highlights cross-sectional brain 18f-fdg pet pet-mapped visual pathways positron emission tomography positron-emission-tomography 18f-fdg pet study magnetic resonance scans mini-mental state examination cell-specific pathology isolates mr-based hippocampal volumetry late-onset alzheimer-type dementia mri-based hippocampal volume 18f-2-deoxyglucose signal article european journal longitudinal fdg-pet studies full article pdf magnetic resonance molecular imaging aims ad-related volume losses privacy choices/manage cookies de leon mj brain glucose metabolism fdg pet imaging cerebral glucose metabolism computer-assisted imaging global deterioration scale regional brain metabolism regional cerebral metabolism high-avidity binding altered glucose metabolism cerebral glucose utilization cerebral metabolic findings quantitative mr volumetry medial temporal lobe european economic area blood–brain barrier age-related memory decline mild cognitive impairment functional brain abnormalities posterior cingulate cortex fdg-pet predict impaired glucose tolerance glut3 glucose transporters

Questions {❓}

Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer’s disease?
Synaptic loss and pathological change in older adults—aging versus disease?
What is cognitive reserve?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease
         description:The demographics of aging suggest a great need for the early diagnosis of dementia and the development of preventive strategies. Neuropathology and structural MRI studies have pointed to the medial temporal lobe (MTL) as the brain region earliest affected in Alzheimer’s disease (AD). MRI findings provide strong evidence that in mild cognitive impairments (MCI), AD-related volume losses can be reproducibly detected in the hippocampus, the entorhinal cortex (EC) and, to a lesser extent, the parahippocampal gyrus; they also indicate that lateral temporal lobe changes are becoming increasingly useful in predicting the transition to dementia. Fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) imaging has revealed glucose metabolic reductions in the parieto-temporal, frontal and posterior cingulate cortices to be the hallmark of AD. Overall, the pattern of cortical metabolic changes has been useful for the prediction of future AD as well as in distinguishing AD from other neurodegenerative diseases. FDG-PET on average achieves 90% sensitivity in identifying AD, although specificity in differentiating AD from other dementias is lower. Moreover, recent MRI-guided FDG-PET studies have shown that MTL hypometabolism is the most specific and sensitive measure for the identification of MCI, while the utility of cortical deficits is controversial. This review highlights cross-sectional, prediction and longitudinal FDG-PET studies and attempts to put into perspective the value of FDG-PET in diagnosing AD-like changes, particularly at an early stage, and in providing diagnostic specificity. The examination of MTL structures, which has so far been exclusive to MRI protocols, is then examined as a possible strategy to improve diagnostic specificity. All told, there is considerable promise that early and specific diagnosis is feasible through a combination of imaging modalities.
         datePublished:2005-03-04T00:00:00Z
         dateModified:2005-03-04T00:00:00Z
         pageStart:486
         pageEnd:510
         sameAs:https://doi.org/10.1007/s00259-005-1762-7
         keywords:
            Alzheimer’s disease
            Positron emission tomography
            Brain metabolism
            Early diagnosis
            Differential diagnosis
            Mild cognitive impairment
            Nuclear Medicine
            Imaging / Radiology
            Orthopedics
            Cardiology
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00259-005-1762-7/MediaObjects/s00259-005-1762-7fhb1.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00259-005-1762-7/MediaObjects/s00259-005-1762-7fhc2.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00259-005-1762-7/MediaObjects/s00259-005-1762-7fhc3.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00259-005-1762-7/MediaObjects/s00259-005-1762-7fhc4.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00259-005-1762-7/MediaObjects/s00259-005-1762-7fhc5.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00259-005-1762-7/MediaObjects/s00259-005-1762-7fhc6.jpg
         isPartOf:
            name:European Journal of Nuclear Medicine and Molecular Imaging
            issn:
               1619-7089
               1619-7070
            volumeNumber:32
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Lisa Mosconi
               affiliation:
                     name:University of Florence
                     address:
                        name:Department of Clinical Pathophysiology, Nuclear Medicine Unit, University of Florence, Italy
                        type:PostalAddress
                     type:Organization
                     name:University School of Medicine
                     address:
                        name:Center for Brain Health, MHL400, Department of Psychiatry New York, University School of Medicine, New York, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease
      description:The demographics of aging suggest a great need for the early diagnosis of dementia and the development of preventive strategies. Neuropathology and structural MRI studies have pointed to the medial temporal lobe (MTL) as the brain region earliest affected in Alzheimer’s disease (AD). MRI findings provide strong evidence that in mild cognitive impairments (MCI), AD-related volume losses can be reproducibly detected in the hippocampus, the entorhinal cortex (EC) and, to a lesser extent, the parahippocampal gyrus; they also indicate that lateral temporal lobe changes are becoming increasingly useful in predicting the transition to dementia. Fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) imaging has revealed glucose metabolic reductions in the parieto-temporal, frontal and posterior cingulate cortices to be the hallmark of AD. Overall, the pattern of cortical metabolic changes has been useful for the prediction of future AD as well as in distinguishing AD from other neurodegenerative diseases. FDG-PET on average achieves 90% sensitivity in identifying AD, although specificity in differentiating AD from other dementias is lower. Moreover, recent MRI-guided FDG-PET studies have shown that MTL hypometabolism is the most specific and sensitive measure for the identification of MCI, while the utility of cortical deficits is controversial. This review highlights cross-sectional, prediction and longitudinal FDG-PET studies and attempts to put into perspective the value of FDG-PET in diagnosing AD-like changes, particularly at an early stage, and in providing diagnostic specificity. The examination of MTL structures, which has so far been exclusive to MRI protocols, is then examined as a possible strategy to improve diagnostic specificity. All told, there is considerable promise that early and specific diagnosis is feasible through a combination of imaging modalities.
      datePublished:2005-03-04T00:00:00Z
      dateModified:2005-03-04T00:00:00Z
      pageStart:486
      pageEnd:510
      sameAs:https://doi.org/10.1007/s00259-005-1762-7
      keywords:
         Alzheimer’s disease
         Positron emission tomography
         Brain metabolism
         Early diagnosis
         Differential diagnosis
         Mild cognitive impairment
         Nuclear Medicine
         Imaging / Radiology
         Orthopedics
         Cardiology
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00259-005-1762-7/MediaObjects/s00259-005-1762-7fhb1.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00259-005-1762-7/MediaObjects/s00259-005-1762-7fhc2.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00259-005-1762-7/MediaObjects/s00259-005-1762-7fhc3.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00259-005-1762-7/MediaObjects/s00259-005-1762-7fhc4.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00259-005-1762-7/MediaObjects/s00259-005-1762-7fhc5.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00259-005-1762-7/MediaObjects/s00259-005-1762-7fhc6.jpg
      isPartOf:
         name:European Journal of Nuclear Medicine and Molecular Imaging
         issn:
            1619-7089
            1619-7070
         volumeNumber:32
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Lisa Mosconi
            affiliation:
                  name:University of Florence
                  address:
                     name:Department of Clinical Pathophysiology, Nuclear Medicine Unit, University of Florence, Italy
                     type:PostalAddress
                  type:Organization
                  name:University School of Medicine
                  address:
                     name:Center for Brain Health, MHL400, Department of Psychiatry New York, University School of Medicine, New York, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:European Journal of Nuclear Medicine and Molecular Imaging
      issn:
         1619-7089
         1619-7070
      volumeNumber:32
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Florence
      address:
         name:Department of Clinical Pathophysiology, Nuclear Medicine Unit, University of Florence, Italy
         type:PostalAddress
      name:University School of Medicine
      address:
         name:Center for Brain Health, MHL400, Department of Psychiatry New York, University School of Medicine, New York, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Lisa Mosconi
      affiliation:
            name:University of Florence
            address:
               name:Department of Clinical Pathophysiology, Nuclear Medicine Unit, University of Florence, Italy
               type:PostalAddress
            type:Organization
            name:University School of Medicine
            address:
               name:Center for Brain Health, MHL400, Department of Psychiatry New York, University School of Medicine, New York, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Clinical Pathophysiology, Nuclear Medicine Unit, University of Florence, Italy
      name:Center for Brain Health, MHL400, Department of Psychiatry New York, University School of Medicine, New York, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(263)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.53s.

LINK . SPRINGER . COM {}